Clinical trial
Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients
NCT03023124 is registered in ClinicalTrials.gov with Italian Sarcoma Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients
- Lead sponsor
- Italian Sarcoma Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 4, 2018
- Completion date
- December 6, 2024
- Enrollment
- 23 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.